Polaryx Therapeutics PLYX
NASDAQ PLYX
$2.04 +0.02 (+0.99%)
As of: Oct 2, 2026 · 2:02 PM EDT

Polaryx Therapeutics (PLYX) Cash from Financing Activities (2025)

Updated

Polaryx Therapeutics' Cash from Financing Activities was $4.47 million in FY2025, down 37.9% from $7.19 million in FY2024.

Analysis

Polaryx Therapeutics (PLYX) Cash from Financing Activities (2025) Analysis & Trends

  • Per Business Quant data, Cash from Financing Activities in earlier years was $7.19 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Polaryx Therapeutics 103.18 Mn 78.80 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 250,000.00
API Access

Polaryx Therapeutics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=PLYX&period=max&api_key=YOUR_API_KEY